SURGE Therapeutics
Cambridge
About SURGE Therapeutics
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $58.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2023)
- Website: surgetx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/surge-therapeutics-61480 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.